Trump administration claims all states will join Medicaid drug pricing program, but several states remain undecided

White House officials announced that every U.S. state had agreed to participate in a new federal Medicaid drug pricing initiative, describing it as a "good deal" for states.

State officials, however, told STAT that many are still weighing the decision. Some have applied but have not committed, while others are assessing whether the GENEROUS model offers better terms than existing rebate arrangements.

The discrepancy highlights uncertainty about the program's value and suggests that the administration's claim of universal state participation may be premature.